Home›The Library›Octreotide
Octreotide (Sandostatin)
Octreotide is the mirror image of this site's entire growth-hormone-secretagogue cluster: instead of trying to provoke GH release, it's a real, decades-approved somatostatin analog that suppresses it. It has been standard medical therapy for acromegaly and carcinoid syndrome since 1988, with real controlled trial evidence, and it's the drug clinicians reach for when a patient's pituitary is making too much growth hormone — the opposite problem sermorelin, CJC-1295, ipamorelin and hexarelin are marketed to solve.
In brief
Should you care? Yes if you've read this site's sermorelin, CJC-1295, ipamorelin or hexarelin pages — octreotide is the real, approved drug that does the opposite of what those are marketed to do.The short version
- FDA-approved since 1988 (Sandostatin) for acromegaly, later carcinoid syndrome symptoms and VIPoma diarrhea.
- Real controlled trial evidence from the drug's original development established both indications.
- Suppresses GH and IGF-1 — the reverse mechanism of every GH-secretagogue peptide covered elsewhere on this site.
What it is
Octreotide is a synthetic analog of somatostatin, the body's own growth-hormone-inhibiting hormone. Developed by Sandoz (now Novartis), it was FDA-approved in 1988 as Sandostatin injection to reduce elevated GH and IGF-1 in acromegaly, and to control the flushing and diarrhea of metastatic carcinoid tumors and VIPomas. A once-monthly intramuscular depot formulation, Sandostatin LAR, followed later.
The trial evidence
An early study (Lamberts et al., N Engl J Med 1985;313:1576-1580) showed sustained suppression of GH and IGF-1 in acromegaly patients over long-term treatment. For carcinoid syndrome, Kvols et al. (N Engl J Med 1986;315(11):663-666, DOI 10.1056/NEJM198609113151102) treated 25 patients with metastatic carcinoid tumors: flushing and diarrhea resolved promptly in 22 of 25, and 18 of 25 (72%) had a ≥50% drop in urinary 5-HIAA sustained for a median of over 12 months. These are real, named, controlled human trials from the drug's original development.
The opposite of a GH secretagogue
Sermorelin, CJC-1295, ipamorelin, hexarelin and GHRP-2/6 — all covered elsewhere on this site, all graded C or D — are marketed to stimulate the pituitary into releasing more growth hormone. Octreotide does the reverse: it's the actual clinical tool used when a patient's pituitary is releasing too much GH, as in acromegaly. It's a useful sanity check on the secretagogue cluster's claims — the real, approved, evidence-backed GH-axis drug on this site suppresses GH, and none of the secretagogues have anything close to this trial base for stimulating it.
Not first-line for acromegaly anymore
Current endocrine society guidelines put transsphenoidal pituitary surgery first for most acromegaly patients, with octreotide and related somatostatin analogs reserved for surgical failures, inoperable tumors, or as a bridge — worth knowing rather than assuming octreotide alone is the modern standard of care.
Where it's used today
Beyond acromegaly and carcinoid syndrome, octreotide is used for esophageal variceal bleeding, severe secretory diarrhea, GI fistula output reduction, and dumping syndrome — genuinely mainstream hospital and endocrinology use, not a peptide-wellness product. We found scattered anecdotal online references to off-label bodybuilding use for suppressing insulin/IGF-1 during anabolic-steroid cycles, but no clinical literature supporting that specific practice — worth flagging as a marketing claim we could not substantiate, not a real, cited use.
References
- Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E, "Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995," N Engl J Med 1985;313:1576-1580.
- Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG, "Treatment of the malignant carcinoid syndrome," N Engl J Med 1986;315(11):663-666, DOI 10.1056/NEJM198609113151102.
- Sandostatin (octreotide) FDA labeling, initial U.S. approval 1988.